Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Central Nervous System Lymphoma (PCNSL)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT00712062
What this trial is testing

Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma

Who this might be right for
Primary Central Nervous System Lymphoma
University of Florida
Testing effectiveness (Phase 2)Study completedNCT00193973
What this trial is testing

Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma

Who this might be right for
Primary Central Nervous System Lymphoma
Trans Tasman Radiation Oncology Group 20
Large-scale testing (Phase 3)Looking for participantsNCT02836158
What this trial is testing

Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

Who this might be right for
Primary Central Nervous System Lymphoma
Navy General Hospital, Beijing 100
Early research (Phase 1)Active Not RecruitingNCT04608487
What this trial is testing

Axi-cel in CNS Lymphoma

Who this might be right for
LymphomaLymphoma Cns
Dana-Farber Cancer Institute 18
Not applicableUnknownNCT03582254
What this trial is testing

Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years

Who this might be right for
Primary Central Nervous System Lymphoma
Assistance Publique - Hôpitaux de Paris 62
Early research (Phase 1)Ended earlyNCT00112619
What this trial is testing

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsCarcinoma of Unknown PrimaryLeukemia+2 more
Pediatric Brain Tumor Consortium 19
Testing effectiveness (Phase 2)Study completedNCT00002940
What this trial is testing

Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS

Who this might be right for
Lymphoma
St. Jude Children's Research Hospital
Testing effectiveness (Phase 2)Looking for participantsNCT05583071
What this trial is testing

Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

Who this might be right for
Non-Hodgkin Lymphoma
University of Cologne 20
Testing effectiveness (Phase 2)Study completedNCT01956695
What this trial is testing

Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma

Who this might be right for
LymphomaRelapse
Institut Curie 45
Not applicableLooking for participantsNCT05011045
What this trial is testing

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Who this might be right for
Central Nervous System LymphomaHematopoietic and Lymphoid Cell NeoplasmLeukemia+3 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04947319
What this trial is testing

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

Who this might be right for
Refractory Primary Central Nervous System LymphomaPrimary CNS Lymphoma
Ono Pharmaceutical Co., Ltd. 119
Not applicableStudy completedNCT03342586
What this trial is testing

Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity

Who this might be right for
Central Nervous System Lymphoma
Memorial Sloan Kettering Cancer Center 14
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07405255
What this trial is testing

Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma

Who this might be right for
Central Nervous System Lymphoma
Ruijin Hospital 19
Testing effectiveness (Phase 2)WithdrawnNCT00003505
What this trial is testing

Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Who this might be right for
Primary Central Nervous System Lymphoma
Burzynski Research Institute
Early research (Phase 1)Study completedNCT00003956
What this trial is testing

Combination Chemotherapy in Treating Patients With Advanced Cancer

Who this might be right for
LymphomaUnspecified Adult Solid Tumor, Protocol Specific
Memorial Sloan Kettering Cancer Center 25
Testing effectiveness (Phase 2)Looking for participantsNCT04906096
What this trial is testing

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Who this might be right for
Primary Central Nervous System LymphomaNon-Hodgkin Lymphoma of Extranodal Site
Lakshmi Nayak, MD 25
Early research (Phase 1)Study completedNCT03798314
What this trial is testing

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

Who this might be right for
Recurrent Nervous System LymphomaRecurrent Primary Vitreoretinal DLBCLRefractory Nervous System Lymphoma+1 more
Mayo Clinic 3
Testing effectiveness (Phase 2)Looking for participantsNCT06931652
What this trial is testing

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

Who this might be right for
Primary CNS Lymphoma (PCNSL)
The Lymphoma Academic Research Organisation 60
Large-scale testing (Phase 3)Active Not RecruitingNCT04931368
What this trial is testing

OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma

Who this might be right for
Primary Central Nervous System Lymphoma
Klinikum Stuttgart 331
Not applicableUnknownNCT05347511
What this trial is testing

Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.

Who this might be right for
Rare Disease With Poor Outcome
Central Hospital, Nancy, France 94
Next Page